Merck & Co., Inc.
MRK
NYSE93.55
Merck & Co., Inc.
NYSE:MRK
RECENT
PRICE
93.55
P/E
RATIO
16.74
(PEG:0.20)
P/E RATIO
RELATIVE
TO S&P
0.65
DIV
YLD
3.26%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
- - Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 05/22:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
Fiscal year
10.02
2.11
2.82
1.52
10.39
2.04
2.66
1.53
11.15
1.51
2.76
1.52
11.17
3.66
2.47
1.54
13.01
6.12
0.92
1.65
14.86
0.28
2.95
1.57
15.80
2.06
3.51
1.58
15.62
2.04
2.67
1.73
15.04
1.50
3.45
1.80
14.88
4.20
1.95
1.85
14.20
1.60
4.00
1.84
14.48
1.43
3.19
1.86
14.88
0.89
1.69
1.92
16.31
2.40
3.20
1.99
18.45
3.88
3.93
2.24
18.97
2.79
2.20
2.46
19.25
5.16
3.82
2.61
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.64
8.16
0.45
8.06
0.47
8.38
0.61
8.78
0.69
28.01
0.54
17.57
0.57
17.93
0.65
17.52
0.53
17.00
0.82
17.14
0.46
16.06
0.59
14.58
0.70
12.73
1.01
10.30
1.37
10.20
1.85
10.01
1.76
15.09
CAPEX per share
Book Value per share
2,197
2,178
2,171
2,136
2,109
3,095
3,041
3,027
2,928
2,838
2,781
2,749
2,697
2,593
2,539
2,530
2,530
Comm.Shares outs.(m)
- -
- -
- -
18.0
0.99
4.17%
32.0
1.85
3.15%
9.6
0.45
4.39%
4.6
0.06
5.90%
123.7
5.97
4.56%
15.8
0.97
4.84%
19.4
1.30
4.39%
29.4
1.73
4.08%
13.0
0.72
3.39%
33.6
1.68
3.42%
38.2
1.72
3.42%
66.5
2.82
3.24%
25.5
1.02
3.26%
20.2
0.83
2.87%
27.5
0.73
3.20%
14.7
0.49
3.44%
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (31/12/21 | Q4)
Total liabilities
$67,437 m.
Total assets
$105,694 m.
Long-term debt
$30,690 m.
Cash and equiv.
$8,096 m.
Goodwill $21,264 m.
Retained earnings $53,696 m.
Common stock 2,527 m. shares
Market Capitalisation
$236,570 m. (as of 21/5/22)
45,987
7.3%
48,047
18.7%
47,267
20.9%
44,033
17.4%
42,237
15.8%
39,498
19.1%
39,807
15.1%
40,122
18.2%
42,294
21.1%
46,840
26.1%
47,994
17.7%
48,704
27.1%
Revenue (m)
Operating margin
7,381
861
7,427
6,272
6,978
6,168
6,988
4,404
6,691
11,920
6,375
4,442
5,441
3,920
4,637
2,394
4,519
6,220
3,652
9,843
3,625
7,067
3,214
13,049
Depreciation (m)
Net profit (m)
40.6%
1.9%
12.8%
13.1%
27.9%
13.0%
18.5%
10.0%
30.9%
28.2%
17.4%
11.2%
15.4%
9.8%
62.9%
6.0%
28.8%
14.7%
14.7%
21.0%
19.4%
14.7%
11.0%
26.8%
Income tax rate
Net profit margin
13,423
15,482
54,376
16,936
15,525
54,517
16,509
16,254
53,020
17,817
20,539
49,765
14,407
18,699
48,647
10,561
23,929
44,676
13,410
24,274
40,088
6,152
21,353
34,336
3,669
19,806
26,701
5,263
22,736
25,907
437
25,360
25,317
6,394
30,690
38,184
Working capital (m)
Long-term debt (m)
Equity (m)
1.5%
2.2%
1.6%
8.0%
7.8%
11.5%
7.9%
9.0%
11.6%
6.0%
6.0%
8.8%
15.6%
18.3%
24.5%
6.1%
6.0%
9.9%
5.8%
5.6%
9.8%
3.9%
8.3%
7.0%
11.2%
11.5%
23.3%
17.1%
14.7%
38.0%
12.1%
10.5%
27.9%
16.7%
14.6%
34.2%
ROIC
Return on capital
Return on equity
Working Capital
2019
2020
2021
Cash assets
10,450
8,836
8,870
Receivables
6,778
7,851
9,230
Inventory
5,978
6,310
5,953
Other
4,277
4,756
6,987
Current assets
27,483
27,764
30,266
Acc. Payable
3,738
4,594
4,609
Debt due
3,610
6,431
2,412
Other
14,872
16,302
16,851
Current liab.
22,220
27,327
23,872
73.0%
180.1%
(463.6)%
70.5%
23.3%
63.2%
15.1%
97.0%
(19.8)%
116.7%
56.0%
233.6%
(15.2)%
83.5%
(30.7)%
97.7%
(115.8)%
201.4%
16.8%
171.7%
42.1%
105.1%
12.1%
134.6%
Plowback ratio
Div.&Repurch. to FCF
Merck & Co., Inc. (US) started trading on June 6, 1946 (cik: 0000310158), operates in the Healthcare sector (Drug Manufacturers—General industry), has 67,000 full-time employees, and is led by Mr. Kenneth Frazier. Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
5.03%
0.47%
Cash flow
32.89%
15.92%
Earnings
68.63%
33.68%
Dividends
6.42%
2.71%
Book value
5.83%
-1.98%
Insider trading
Type
Shares
Date
Oosthuizen Johannes Jacobus
Award
21,359
05/04/22
Oosthuizen Johannes Jacobus
Exempt
907
05/04/22
Oosthuizen Johannes Jacobus
InKind
447
05/04/22
Oosthuizen Johannes Jacobus
Exempt
907
05/04/22
Karachun Rita A
Exempt
949
05/04/22
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2019
10,816
11,760
12,397
11,868
46,841
2020
12,057
10,872
12,551
12,515
47,995
2021
12,080
11,402
13,154
13,521
50,157
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2019
1.15
1.05
0.75
0.93
3.88
2020
1.27
1.19
1.16
(0.83)
2.79
2021
1.26
0.61
1.81
1.49
5.16
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2019
0.56
0.58
0.55
0.55
2.24
2020
0.61
0.62
0.61
0.61
2.46
2021
0.65
0.66
0.65
0.65
2.61
03/14/2022
Merck’s Covid-19 Pill Heavily Used So Far Despite Concerns
The Wall Street Journal - Read more...
02/03/2022
Merck, Eli Lilly Covid-19 Treatments Power Quarterly Sales Gains
The Wall Street Journal - Read more...
02/03/2022
Meta, Amazon, Snap, Pinterest: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
01/28/2022
Merck’s Covid-19 Pill Shows Promise Against Omicron
The Wall Street Journal - Read more...
01/07/2022
GameStop, AMC, DraftKings, Starbucks: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
12/23/2021
FDA Authorizes Merck’s Covid-19 Pill for At-Home Treatment
The Wall Street Journal - Read more...
12/01/2021
Salesforce, Snowflake, Zscaler, Box: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
11/30/2021
Omicron Variant Sends Policy Makers Scrambling as Science Lags Behind
The Wall Street Journal - Read more...
11/30/2021
Peloton, Moderna, Marriott, Pfizer: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
11/29/2021
Moderna, Coinbase, Occidental, Royal Caribbean: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
11/26/2021
Merck’s Covid-19 Pill Was 30% Effective in Final Analysis
The Wall Street Journal - Read more...
11/08/2021
Tesla, Coinbase, Merck: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
11/04/2021
Tesla, Moderna, Zillow, Qualcomm, Qorvo: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
11/04/2021
Merck Covid-19 Pill Cleared for Use in U.K., Its First Authorization
The Wall Street Journal - Read more...
10/28/2021
Shiba Inu Coin, Tesla, Ford, Nokia: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
10/27/2021
Promising Covid-19 Pill Licensed to Nonprofit to Increase Global Supply
The Wall Street Journal - Read more...
10/12/2021
Airbnb, Merck, High Tide, Square: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
10/11/2021
Merck Asks FDA to Authorize Promising Covid-19 Pill
The Wall Street Journal - Read more...
10/11/2021
Marathon Digital, Occidental, Southwest: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
10/04/2021
Tesla, Merck, Moderna: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
10/01/2021
Merck Pill Intended to Treat Covid-19 Succeeds in Key Study
The Wall Street Journal - Read more...
10/01/2021
AMC, Bitcoin, Lordstown, Merck: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
09/30/2021
Merck to Buy Acceleron Pharma for $11.5 Billion
The Wall Street Journal - Read more...
09/30/2021
Virgin Galactic, Camber Energy, Bed Bath & Beyond, Jefferies: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
09/28/2021
Facebook, Ford, Acceleron Pharma: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
09/27/2021
Merck Nears Deal to Acquire Acceleron Pharma
The Wall Street Journal - Read more...
07/25/2021
Race for Covid-19 Pill Heats Up
The Wall Street Journal - Read more...
04/29/2021
Facebook, Twitter, eBay, Apple: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
03/24/2021
Merck Names 30-Year Company Veteran as CFO
The Wall Street Journal - Read more...
03/15/2021
Gilead and Merck Join Forces to Develop Long-Acting HIV Treatment
The Wall Street Journal - Read more...
03/07/2021
U.S. Scientists Question Single Dose for Pfizer, Moderna Shots
The Wall Street Journal - Read more...
03/03/2021
Biden Says U.S. to Have Vaccines for All Adults by End of May
The Wall Street Journal - Read more...
02/05/2021
Merck CFO Brings Corporate Strategy Experience to CEO Role
The Wall Street Journal - Read more...
02/04/2021
Merck’s Kenneth Frazier to Retire as CEO
The Wall Street Journal - Read more...
01/25/2021
Merck Scraps Covid Vaccine Candidates
The Wall Street Journal - Read more...
01/25/2021
GameStop, BlackBerry, Moderna: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
01/06/2021
CEOs Ponder Holding Back Campaign Money
The Wall Street Journal - Read more...
11/23/2020
Merck to Buy OncoImmune for $425 Million Amid Race for Covid-19 Treatments
The Wall Street Journal - Read more...
10/23/2020
Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase
The Wall Street Journal - Read more...
10/02/2020
Merck’s R&D Chief to Retire
The Wall Street Journal - Read more...
09/14/2020
Merck to Invest $1 Billion in Seattle Genetics
The Wall Street Journal - Read more...
09/11/2020
Merck Covid-19 Vaccine Begins Human Testing
The Wall Street Journal - Read more...